Selective targeting of transforming growth factor-beta1 into TCR/CD28 signalling plasma membrane domains silences T cell activation by unknown
Harder et al. Cell Communication and Signaling 2014, 12:74
http://www.biosignaling.com/content/12/1/74RESEARCH Open AccessSelective targeting of transforming growth
factor-beta1 into TCR/CD28 signalling plasma
membrane domains silences T cell activation
Thomas Harder*, Karina Guttek, Lars Philipsen, Luca Simeoni, Burkhart Schraven and Dirk ReinholdAbstract
TGFβ1 (Transforming Growth Factor-beta1) is a versatile regulator of T cell immune responses. Depending on its
context in the immunological environment, TGFβ1 guides T cells toward specific activation programs including
TH17 and regulatory T cell activities. Moreover, TGFβ signals function in immune homeostasis by directly attenuating
T cell effector activities. We uncovered a novel context under which TGFβ1 stringently and reversibly silences
activation responses of resting human T cells to TCR/CD28 stimulating surfaces:
Using ligand-presenting beads, TGFβ1 and TCR/CD28-activating signals were directed into defined plasma
membrane domains of T cells. Selective targeting of TGFβ1 cytokine into TCR/CD28 signalling plasma membrane
domains held back early response of TCR-proximal tyrosine phosphorylation and bead engulfment at activation
sites. Consequently, downstream induction of proliferation and cytokine secretion were stringently attenuated.
After extended incubation with TGFβ1-presenting beads, silenced T cells became receptive again to activation by
renewed TCR/CD28-stimuli, indicating that the unresponsive state of T cells was reverted and did not reflect
long-lasting anergy or decrease in T cell viability. These findings outline a new strategy of physically linking TGFβ1 and
TCR-activating functions for the treatment of disease and pathological conditions which are caused by unwanted T
cell activity.
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The human body is permanently exposed to pathogens
like viruses which infect cells of the body and cause dis-
ease. In order to control pathogen attack, humans and
animal species have evolved a sophisticated defence; the
immune system. The immune system needs to recognise
pathogens, fend them off, and memorise these pathogens
in case they reappear. However, loss of control over these
defence mechanisms is a cause of many serious diseases
like diabetes, inflammatory bowel disease, multiple scler-
osis, and allergies. In the present study we developed a
set-up under which key cells of the immune system; so-
called T cells, are held in a dormant state under which
they do not activate their functions in immune defence.
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unless otherwise stated.treatment of numerous important diseases which are
caused by unwanted action of T cells like diabetes, inflam-
matory bowel disease, multiple sclerosis, and allergies.Background
Transforming growth factor-beta (TGFβ) has pleiotropic
roles in steering differentiation and homeostasis of cells,
tissues, and organs [1]. TGFβ1 is a versatile regulator of T
cell immune responses and guides CD4+ T lymphocytes
toward specific activities of the TH17 and Treg phenotypes
[2,3]. Additionally, TGFβ signals restrain T cell activities
and thereby directly function in immune homeostasis
[4,5]. Functions of TGFβ1 in safeguarding a healthy bal-
ance of the immune system were highlighted by severe
multiorgan inflammatory disease of TGFβ1-deficient mice
[6,7]. Dysfunction of TGFβ1-mediated T cell balance is as-
sociated with autoimmune disorders and thus molecularLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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important medical interest.
TGFβ signals are transduced by TGFβ receptors (TGFβR)
I and II which catalyse serine/threonine phosphorylation
of SMAD proteins. Phosphorylated SMADs cooperate
with various transcription factors to activate cell-specific
gene transcription programs. TGFβ receptors, cytoplasmic
and nuclear factors, and chromatin structure determine
context-dependent cellular outcomes of these canonical
TGFβ signalling cascades. Additional non-canonical TGFβ
signalling pathways exist, many of which are initiated at
the platform of the plasma membrane for example by
targeting PI3K/AKT pathway and Rho-GTPase signalling
cascades [1].
Under physiological, resting conditions TGFβ is held
in an inactive latent configuration in a complex with
Latency Associated Peptide (LAP) which hinders TGFβ
cytokine binding to TGFβ receptors. Latent TGFβ gets
activated when active cytokine is released from TGFβ-
LAP complex. Various mechanisms mediate activation
of TGFβ: These include specific binding of proteins like
thrombospondin to LAP, LAP proteolytic cleavage, αv
integrin-binding and cytoskeletal force along membrane-
bound TGFβ-LAP complex [8-10].
T cell antigen receptor (TCR), upon interaction with
a cognate peptide-MHC ligand, transduces key signals
which activate resting T lymphocytes to proliferate and
perform immune effector functions. These signals are
propagated to the T cell interior via tyrosine kinase
activation and induction of signalling complexes which
mediate intracellular signalling reactions and respective
T cell responses [11]. A costimulatory second signal is
mediated by surface protein CD28 on engagement with
CD80/86 antigens on antigen-presenting cells and is
required for full activation of resting T lymphocytes to
proliferate and perform effector functions like secretion
of cytokines [12].
TGFβ1-LAP is presented on the surface of CD4+
CD25+ T cells and was proposed to exert regulatory
functions upon contact with effector T cells [13,14]. On
FoxP3+ regulatory T cells (Tregs) TGFβ1-LAP is bound
to trans-plasma membrane protein GARP (glycoprotein A
repetitions predominant protein) [15,16]. siRNA-mediated
depletion of GARP in human Tregs reduced, but did not
abolish, suppressive activity of FoxP3+ Tregs in vitro, indi-
cating contribution of TGFβ1 surface presentation as well
as additional functions to regulatory activities of Tregs [16].
A distinct population of FoxP3+ human Tregs expresses
MHC class II and was shown to specifically mediate
early suppression of T cell activation directly upon cell/cell
contact [17].
TCR activation and TGFβ1-signals may likewise act
together at the immunological synapse between CD4+ T
cells and antigen-presenting dendritic cells (DC) in orderto induce Treg and TH17 activities. These DCs need to
express matching MHC class II to activate TCR and αv
integrins which present TGFβ1 to T cells [18-20].
Hence, simultaneous presentation of TGFβ1 and TCR-
activating ligands on cell surfaces is a recurring motif in
modulation of T cell activities. Here we used defined
ligand-coated beads as artificial surfaces to present acti-
vating stimuli to resting human T cells in vitro: Simul-
taneous presentation of TGFβ1 and TCR/CD28-signals
in common T cell plasma membrane signalling domains
stringently and reversibly held back activation responses
of T cells. These findings identified lateral plasma mem-
brane compartmentalization of TGFβ1 signalling as cell
biological context under which T cell activation responses
are attenuated and suggest new strategies for treatment of
disease and pathological conditions which are caused by
unwanted T cell activity.
Results and discussion
Presentation of TGFβ1 on TCR/CD28-activating beads
silences T cell activation responses
Isolated resting human T lymphocytes were activated via
TCR/CD28 by conjugation with protein G-coated microbe-
ads which were coated with anti-CD3 and anti-CD28
mAbs (monoclonal antibodies) and, additionally, with mAb
against the LAP subunit of latent TGFβ-LAP complex.
Defined amounts of TGFβ1-LAP were loaded onto anti-
CD3/CD28/LAP beads via anti-LAP antibodies. TGFβ1-
LAP-loading silenced proliferative response of T cells
to bead-bound anti-CD3 and anti-CD28 mAbs in
strictly dose-dependent manner; first evident around
2 ng/ml final concentration and nearing completion at
50 ng/ml (Figure 1A).
We estimated contribution of steric impediment of
antibody access to T cells by bead-bound TGFβ1-LAP to
attenuation of T cell proliferation response. In parallel
experiments TCR/CD28-activating beads were loaded
with inactive LAP and with latent TGFβ1-LAP. Inactive
LAP, when loaded on T cell-activating anti-CD3/CD28/
LAP beads, partially inhibited proliferation at highest
doses (Figure 1B) indicating that steric impediment of
activating antibody access contributes to the inhibitory
effect. This, however, can be discriminated from strictly
dose-dependent and stringent antiproliferative activity of
TGFβ1-LAP on activating beads.
We then assessed whether presentation of TGFβ1-LAP
on anti-CD3/CD28/LAP beads also attenuated early re-
sponse of tyrosine phosphorylation of TCR-proximal
signalling proteins [21]. Western blots of whole cell
lysates of TCR/CD28 activating bead-stimulated T cells
were performed over a time course of 30 mins, 37°C in-
cubation. These blots reiterated TCR triggering-induced
tyrosine phosphorylation of tyrosine kinase ZAP-70,
transmembrane Linker for Activation of T cells (LAT)
Figure 1 A-D Attenuation of T cell activation response by TGFβ1-LAP-loaded on anti-CD3/CD28/LAP beads. A) TGFβ1-LAP on anti-CD3/
CD28/LAP activating beads, shown in ng/ml final concentration, holds back bead-induced proliferation of human T lymphocytes in dose-dependent
manner, nearing a complete attenuation at highest doses. Proliferation was assayed by [3H]thymidine incorporation, depicted in counts per minute
(cpm). Data present averages and SEMs of 3 independent experiments with hexuplicate cultures each. B) Inactive LAP and TGFβ1-LAP were loaded
onto anti-CD3/CD28/LAP beads in parallel titrations. TGFβ1-LAP on activating beads recapitulated dose-dependent silencing of T cell proliferative
response to TCR/CD28 activation. Loading of LAP elicited significant inhibition of proliferation only at highest doses (n = 4). **, *** depict respective
significant difference of p <0.01, 0.005 to 100% proliferation response elicited by anti-CD3/CD28/LAP beads. C) Western blots show that bead-induced
tyrosine phosphorylation of TCR-proximal signalling proteins PLCγ, ZAP-70, and LAT is attenuated by TGFβ1 presentation on anti-CD3/CD28/LAP beads.
β-actin was probed as a loading control. Representative anti-phosphotyrosine blots of 3 independent experiments are shown. D) Gradual release of
TGFβ1 cytokine by TGFβ1-LAP-loaded beads into the aqueous supernatant of ELISA wells.
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70 kD, 36 kD and 110 kD (Figure 1C). Importantly,
when TGFβ1-LAP was presented by TCR/CD28-activat-
ing beads, tyrosine phosphorylation of ZAP-70, LAT, and
PLCγ was reduced. These data suggest that silencing of T
cell activation responses upon TGFβ1-LAP presentation
on TCR/CD28-activating beads commences with attenu-
ation of early TCR-proximal tyrosine phosphorylation.
Holding back T cell activation response by local pres-
entation of latent TGFβ1-LAP implied mechanisms
which release active TGFβ1-cytokine toward TCR/CD28
activation domains. ELISA analysis of bead supernatants
indicated spontaneous release of TGFβ1-cytokine from
beads at a slow rate (Figure 1D) which may be sufficient
for the T cell-silencing mechanism described here. Pres-
ence of T cells elicited an additional ~30% release of
TGFβ1 at 24 h 37°C incubation. Association/dissociation
kinetics of TGFβ-LAP complexes and of TGFβ with
TGFβRI and II were comprehensively characterized in
plasmon resonance studies [22], unravelling rates of spon-
taneous slow dissociation and rapid rebinding of TGFβ1
to LAP, consistent with our results. In our ELISA assaysbead-bound non-complexed LAP molecules compete
with TGFβ-capturing ELISA antibodies for binding free
TGFβ1 cytokine. Moreover, T cellular activities partially
contribute to latent TGFβ1-LAP activation. In conclusion,
our ELISAs demonstrated gradual release of active TGFβ1
cytokine from beads but could not estimate quantities and
rates in T cell/bead-conjugates.
TGFβ and TCR/CD28 signals cooperate in common plasma
membrane domains in order to silence T cell proliferative
response
We next queried the requirement of simultaneously
presenting TCR/CD28 activating stimulus and TGFβ1
activity on the same bead for holding back T-cell prolifera-
tion (Figure 2AB). This was addressed by presenting anti-
CD3/CD28 stimulus and TGFβ1-LAP on separate beads
(Figure 2A). TGFβ1-LAP was presented by protein G
beads which were either coated with anti-LAP antibodies
alone or with anti-LAP and anti-CD28 antibodies at a 1:1
ratio in order to enhance contact of anti-LAP beads with
T cells. Importantly, both ways of presenting TGFβ1-LAP
to T cells had little influence on proliferative response
Figure 2 A, B Selective targeting of TGFβ1 into TCR/CD28 activation sites attenuates T cell proliferation response. A) TGFβ1-LAP, when
presented to human T lymphocytes by anti-LAP- (grey triangles) or anti-LAP/CD28- (white squares) antibody-coated protein G beads, does not
inhibit proliferative response elicited by separate anti-CD3/CD28 antibody-coated beads (n = 3). TGFβ1-LAP presented on anti-CD3/CD28/LAP
beads (black circles) effectively held back proliferation (n = 4). B) Soluble TGFβ1, as latent TGFβ1-LAP (black circles) or active TGFβ1 cytokine
(white squares), was present in equimolar amounts as TGFβ1-LAP for Figures 1A, 2A and did not effectively hold back T cell proliferation induced
by activating anti-CD3/CD28 beads.
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stringent silencing of T cell proliferative response only oc-
curred when TCR/CD28 activating stimuli and TGFβ1-
LAP were presented to T cells together on the same bead.
TGFβ1 was presented to T cells as soluble latent TGFβ1-
LAP complex or as soluble active TGFβ1 cytokine and
elicited little antiproliferative effect on T cells which were
activated by anti-CD3/CD28 protein G beads (Figure 2B).
It is particularly important to emphasise that, at this
specific setting of T cell activation, soluble active TGFβ1
cytokine could not substitute for the lack of TGFβ1
presentation on T cell activating beads in blocking activa-
tion response; suggesting that TCR/CD28- and TGFβ-
signals integrate and cooperate in common T cell plasma
membrane domains and then provide signals which
silence T cell activation response. Interestingly, MHC
class II expression identifies a distinct population of
human Tregs which mediates early suppression of effector
T cell activation responses on direct cell/cell contact [17].
It is tempting to speculate that silencing beads mimic sup-
pressive activities of this MHC class II + Treg population
in the human system.
Diminished proliferative response of bead-silenced T cells
to TCR/CD28-activating culture plates
We observed that TGFβ1 elicits potent inhibition of T
cell proliferative response when presented in physical
proximity of activating TCR/CD28 stimuli. We sought to
characterize response of these TGFβ1-silenced T cells
when activated by fresh, independent TCR/CD28 stimulus
(Figure 3AB). First, T cells were silenced for 15 min at
37°C with TGFβ1-LAP on anti-CD3/CD28/LAP beads
(Figure 3A). T cell/bead conjugates were then transferred
to tissue culture plates which were either left untreated
or were coated with anti-CD3 and anti-CD28 antibodies.After 3 days on plates T cell proliferation rates were de-
termined. 3H-thymidin incorporation was used to meas-
ure T cell proliferation rates. On transfer to uncoated
non-activating plates proliferation was induced by acti-
vating beads without TGFβ1-LAP loading at 15635 ±
9310 cpm SEM and was taken as 100% proliferative re-
sponse value. Variation and relatively low proliferation
rates may be caused by variable loss of T cell/bead con-
tact on transfer. Dose-dependent and stringent antipro-
liferative action of bead-bound TGFβ1-LAP, however, was
always recapitulated. Transfer of 15 min-incubated T cells/
beads to anti-CD3/CD28-coated tissue culture plates
strongly enhanced T cell proliferation rates. Proliferative re-
sponse to plate-bound anti-CD3/CD28-activating stimulus
was significantly attenuated to ~31% by TGFβ1-LAP pres-
entation on initial activating beads. These results indicate
that T cells which were silenced by anti-CD3/CD28/LAP
bead-presented TGFβ1 for 15 min exhibited a reduced re-
sponse to fresh TCR/CD28 activating surface.
Next, initial bead/T cell activation reactions were
incubated for 24 h before transfer to tissue culture plates
(Figure 3B): On transfer to uncoated plates bead-induced
proliferation without TGFβ1-LAP was measured at 47881 ±
12792 cpm SEM. Again proliferation of T cells was inhib-
ited by TGFβ1-LAP loaded on TCR/CD28-activating
beads (Figure 3B). Here however, TGFβ1-mediated sup-
pression of T cell proliferation was less pronounced than
for bead/T cell conjugates after 15 min preincubation in
Figure 3A. This suggested that after 24 h of preincubation
silencing activity of TGFβ1-LAP-loaded TCR/CD28-
activating beads was reduced, and that silenced T cells
reverted to be receptive to renewed proliferative stimulus
by fresh contact with bead-bound anti-CD3/CD28 anti-
bodies on transfer. Indeed, 24 h-preincubated T cells
responded to anti-CD3 and anti-CD28 on plates with little
Figure 3 Attenuated proliferative response of bead-silenced T cells to TCR/CD28-activating culture dishes. T cells were incubated in
round-bottom tubes with anti-CD3/CD28/LAP beads which were loaded with indicated amounts of TGFβ1-LAP. After A) 15 min and B) 24 h
bead/T cell activation reactions were transferred onto tissue culture plates which were either left untreated (black bars) or were coated with
anti-CD3 and anti-CD28 antibodies (grey bars) *, **, *** depict significant (p <0.05, 0.01, 0.005) attenuation of proliferation rates when T cells were
preincubated with TGFβ1-LAP on activating beads. A) Transfer of 15 min-incubated bead/T cell conjugates to uncoated plates recapitulated
dose-dependent attenuation of T cell proliferation by TGFβ1-LAP on activating beads. These T cells strongly responded to independent anti-CD3/CD28
stimulus on culture plates. This additional proliferative response was inhibited by initial TGFβ1-LAP-presentation in dose-dependent manner; down
to ~31% at highest loading of TGFβ1-LAP (n = 4). B) After 24 h of bead/T cell preincubation T cells responded with additional proliferation to
plate-bound anti-CD3/CD28 antibodies. Proliferation on anti-CD3/CD28 plates, however, was restored to nearly the same rates with and without
TGFβ1-LAP preincubation on beads; down to ~85% at highest doses (n = 3).
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cubation was performed with or without TGFβ1-LAP on
activating beads. In conclusion, silencing of T cells by
TGFβ1-LAP-loaded beads was reverted on longer incuba-
tions and thus did not reflect a long-lasting T cell anergic
state or T cell death (Additional file 1: Figure S1 documents
that T cell viability is unaltered under all experimental
conditions).
A range of T cell functions is attenuated when TGFβ1 is
presented on activating beads
A pan human T cell cytokine array was used to cha-
racterize the range of T cell effector responses which
were silenced by TGFβ1-presentation on TCR/CD28-Figure 4 A, B Cytokine array of human pan T cell cytokine secretion-p
beads induced cytokine secretion (black bars) over non-activating control b
beads suppressed activation-induced secretion of cytokines in a dose-depe
T cells showed little induction following TCR-activation were not affected b
was performed once and is detailed in Additional file 2: Figure S2.activating beads (Figure 4). As expected, activating beads
alone induced secretion of cytokines IFN-γ, IL-2, IL-4,
IL-10, IL-17, TNF-α. Consistent with attenuated TCR-
proximal tyrosine phosphorylation and T cell prolifera-
tion, bead-bound TGFβ1-LAP held back secretion of these
cytokines in dose-dependent manner to nearly baseline
levels (Figure 4A). T cell effector functions which were at-
tenuated by TGFβ1-LAP on activating beads included
inflammatory responses (TNF-α), TH1 and TH2 functions
(IFN-γ, IL-4), TH17 functions (IL-17) and regulatory T cell
activities (IL-10). Other cytokines, like IL-8 and IL-16 were
secreted by resting T cells and showed little induction fol-
lowing TCR-activation (Figure 4B). Consistently, secretion
of these cytokines was not altered by TGFβ1 presentationrofiles. A) TCR/CD28 activating-antibodies on anti-CD3/CD28/LAP
eads (white bars). Loading of TGFβ1-LAP on these TCR/CD28 activating
ndent manner (grey bars). B) Cytokines which were secreted by resting
y TGFβ1 on TCR/CD28 activating beads. The cytokine array analysis
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was performed once and is fully documented in Additional
file 2: Figure S2.
TGFβ1-presentation hinders spreading of T cells over
TCR/CD28-activating bead surface
Next, spreading of T cells over anti-CD3/CD28/LAP
bead surfaces with and without TGFβ1-LAP loading was
characterized by epifluorescence microscopy and statis-
tical analysis (Figure 5). Bead/T cell conjugates, after
45 min incubation at 37°C, were stained with Alexa488
fluorescent anti-actin mAb to visualize the circumference
of T cells, and protein G beads were additionally marked
with Alexa555 mouse IgG1. Consistent with previous
reports, anti-CD3/CD28/LAP antibodies alone induced T
cell-spreading over the surface of TCR/CD28-activating
beads leading to their engulfment (Figure 5A) and actin-
containing structures formed at the edges of the beads
while actin was depleted from the central region of bead-
cell contact [23,24]. Importantly, loading of TGFβ1-LAP
on activating beads significantly inhibited engulfment of
TCR/CD28-activating beads (Figure 5B, C). Inhibition of T
cell spreading over TCR-activating surfaces was reported
to attenuate T cell activation response [23,25].
Conclusions
Pleiotropic action and consequent severe side effects
preclude use of active TGFβ in medical applicationsFigure 5 A, B Spreading of T cells over TCR/CD28-activating bead sur
CD28/LAP beads and incubated at 37°C for 45 min and analysed by fluores
Alexa488 anti-actin mAb (in green in merged image, please note weak bin
Alexa555 IgG1 mAb (in red). A) Anti-CD3/CD28/LAP beads triggered spread
engulfment. Actin was depleted from the centre of bead/ T cell contact r
CD28-mediated bead-engulfment by T cells and actin reorganisation was
Scale bar =10 μm. C) Bar graphs indicate diameter of contact area of 23 (
independent experiments. Boxes mark the 25% and 75% percentiles and
significant difference of p < 0.0001 in two-tailed Mann–Whitney testing. P
TGFβ1 cannot be graphed separately.for the treatment of pathological conditions connected to
unwanted T cell activity [26]. Our findings suggest a new
strategy to circumvent these difficulties by selective tar-
geting of TGFβ1 to TCR activation plasma membrane
domains in order to specifically silence T cell responses.
Bifunctional biologicals which link functions of TCR acti-
vation and TGFβRI and II activation proximally in the
plasma membrane promise applications in therapy of dis-
ease associated to unbalanced, unwanted T cell activity in
autoimmunity, allergy or transplant rejection.
Methods
Materials
Protein G-coated dynabeads were obtained from Novex
Life technologies. Pan T cell isolation kit II was from
Miltenyi Biotec. HIT3a anti-CD3 mAb and CD28.2
anti-CD28 mAb were from Becton Dickinson. Anti-
LAP-TGFβ mAb; latent TGFβ1,; active TGFβ1 cytokine,
cytokine array kit and TGFβ cytokine ELISA assay were
from R&D Systems. Anti-phospho-PLCγ1 (Tyr783),
anti-phospho-Zap-70 (Tyr319), and anti-phospho-LAT
(Tyr191) were obtained from Cell Signaling Technology,
anti-β-Actin monoclonal antibody from Sigma. HRP-
conjugated donkey anti-mouse IgG or donkey anti -rabbit
IgG (Dianova, Hamburg, Germany) were used as sec-
ondary antibodies. Ficoll was from Biochrome, [3H]thy-
midine from MP Biomedicals, AIM-V culture medium
from Invitrogen.face. Isolated human resting T cells were conjugated with anti-CD3/
cence microscopy. Outline of T cells was marked with fluorescent
ding of Alexa488 mAb to protein G beads), protein G beads with
of cells over bead surface leading to their partial or complete
egion and actin-rich lamellipodia formed at the periphery. B) TCR/
suppressed in conjugates with TGFβ1-presenting activating beads.
0 ng/ml TGFβ1) or 14 (20 ng/ml TGFβ1) bead/cell conjugates in two
error bars 5% and 95% percentiles of the contact secants. *** mark
lease note that 5% and 25% percentiles in data sets of 0 ng/ml
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Human peripheral blood mononuclear cells (PBMC) were
isolated by Ficoll gradient centrifugation of heparinized
blood collected from healthy volunteers. Human T cells
were further purified by non-T cell depletion using the
Pan T cell isolation kit II (Miltenyi Biotec). Purity of
isolated pan T cells was ≥99%. Cells were washed twice
and resuspended in serum-free AIM-V culture medium
(Invitrogen). The study was approved by the local ethics
committee of the Medical Faculty of the Otto-von-
Guericke University Magdeburg. Blood donors gave writ-
ten informed consent.
Ligand-coating of beads, ELISA analysis, and preparation
of anti-CD3/CD28 antibody-bound tissue culture plates
0.6 mg of protein G dynabeads were coated with 11 μg
of antibody mix; anti-CD3, anti-CD28 and anti-LAP
antibodies at 1:5:5 ratios; anti-LAP, anti-CD28 antibodies
at 1:1 ratios, or anti-LAP antibodies alone. After wash in
2×1 ml PBS, 0.5% BSA beads were suspended in 800 μl
PBS, 0.5% BSA for microscopy, ELISAs, array analysis,
and proliferation assays or in 80 μl PBS, 0.5% BSA for
preparing Western blot samples. Antibody-coated beads
in required minimal volumes were incubated with TGFβ1-
LAP to achieve final concentrations of 0, 0.1, 0.2, 0.5, 1, 2,
and 5 ng/ 4 μl of bead suspension. Anti-CD3/CD28/LAP
beads for Western blot samples were loaded to 20 ng
TGFβ1-LAP /4 μl suspension. Bead/TGFβ1-LAP mix was
incubated o/n on a rotating wheel at 4°C, suspended in
1 ml of PBS, 0.5% BSA in ice and harvested with a magnet.
Pelleted beads were then suspended in PBS, 0.5% BSA,
retaining above concentrations of beads and bead-bound
TGFβ1-LAP.
ELISA: 3 μg anti-CD3/CD28/LAP protein G beads were
loaded with 5 ng latent TGFβ1-LAP, transferred into
100 μl AIMV medium in commercial TGFβ-ELISA wells
(BD Life Technologies) and incubated for 1 h (grey bars)
and 24 h (black bars) at 37°C. 105 T cells were present in
some wells. Plates were developed according to manufac-
turer’s instruction in quadruplicate wells per condition.
Plastic tissue culture plates were coated with goat anti-
mouse secondary antibodies (Dianova) 1:100 in PBS 50 μl/
well o/n at 4°C, washed in PBS, and then incubated for
1 h with hybridoma supernatants of anti-CD3 (Okt3) and
anti-CD28 (CD28.2) monoclonal antibodies; 1:100 in PBS.
Proliferation-, cytokine secretion-assay, viability
assessment and Western blot
105 T cells were incubated with 4 μl (2x105) of respective
ligand-coated beads in round bottom wells of 96 well
microtiter plates (Nunc) with 100 μl of serum-free AIM-V
medium (six wells per condition). Proliferation was assessed
after 3 days by measuring [3H]thymidine [3H-TdR] incorp-
oration. [3H]thymidine was added at 0.2 μCi/well for 3 h.At the end of the incubation period, cells were harvested
and radioisotope incorporation was measured as index of
lymphocyte proliferation using a betaplate liquid scintilla-
tion counter (MicroBeta, Wallac).
Cytokine secretion profile following 3 days of cell/bead
incubation was determined from 10x100 μl AIM-V T cell
supernatant per condition and was assayed using commer-
cial cytokine array kit (R&D) according to manufacturer’s
instruction. Semi-quantitative analysis was performed by
determining the background-subtracted sum intensity for
each dot on the membrane using Kodak D1 3.6 software.
Densitometry values of spots on different membranes were
normalized using the results for the positive controls.
Data were analysed, graphed, and subjected to statistical
analyses using Graphpad Prism software.*, **, *** depict
statistical significance p <0.05, 0.01, 0.005, respectively
assessed by one way Anova testing.
Cell viability was determined in parallel cell cultures
by propidium iodide (PI) staining. After 4 h, 24 h, and
72 h of incubation with respective activating beads, cells
were incubated with PI/RNase staining buffer (BD Phar-
mingen) for 15 min and percentage of PI-excluding cells
was subsequently determined by FACS according to
manufacturer’s instructions.
For Western blot analyses whole cell lysates were pre-
pared from 106 T cells in 20 μl AIM-V medium. T cells
were incubated with 4 μl (2×106) TCR/CD28 activating
beads with and without TGFβ1-LAP coating, incubated
at 37°C for 0, 1, 5, 30 min, and lysed in a final volume of
100 μl 1x SDS sample buffer. Proteins, 20 μl sample per
lane, were separated in 10% SDS-polyacrylamide gel and
transferred to Hybond N membranes by semi-dry blot-
ting. Specific binding was visualized by chemilumines-
cence (Thermo Scientific, Rockford, USA).
Microscopy
Bead/Cell conjugates were incubated at 37°C for 45 min
and adhered to poly-L-lysine coated microscopy slides.
After 15 min fixation with 2% PFA cells were permeabi-
lised for 10 min with 0.2% TX100 in PBS, washed in PBS/
1% BSA for 30 min. Actin of cells was labelled with an
Alexa488 conjugated anti- actin antibody (BD, 558623)
and protein G beads were marked with Alexa555-labelled
IgG1 mAb (Cell Signaling). Fluorescence images were
recorded with a CCD camera (Apogee, KX4) mounted
to a fluorescence microscope (Leica, DM IRE2) using
Alexa488 (Omega Filters, XF116-2) and Alexa555 (Omega
Filters, XF111-2) channel settings at 63x magnification
(Leica, Oil, NA 1.40, 506206). Maximal lengths of the
secants in 14 (20 ng TGFβ1-LAP) and 23 (0 ng TGFβ1-
LAP) at the respective bead/cell contact zones was mea-
sured. *** mark significant inhibition (p < 0.0001) of bead
engulfment by TGFβ1-LAP-loading in two tailed Mann–
Whitney testing.
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Additional file 1: Figure S1. Viability of T cells is unchanged on
presentation of TGFβ1-LAP on TCR/CD28-activating beads. Bead T cell
conjugates were incubated for indicated times at 37°C and percentage of
viable, propidium iodide-excluding cells was determined by FACS analysis.
Additional file 2: Figure S2. Documentation; Cytokine array analysis. A)
Arrangement of cytokine-trapping antibodies on array, B) Chemiluminescence
film exposure C) Semi-quantitative analysis of cytokine-chemiluminescence
signals using software Kodak D1 3.6.
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